Auto-generated: November 11 2019 10:26 PM GMT

175
Stars
Star This?

Source: Leuk Lymphoma  |  Posted 5 years ago

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase; Chuah C, Nakamae H, Shen Z, Bradley-Garelik M, Kim D; Leukemia and Lymphoma (Dec 2013)

Abstract Asian patients with chronic myeloid leukemia (CML) tend to have different characteristics compared with patients from other regions, including younger age and smaller body size. The phase 3, open-label, randomized DASISION trial (NCT00481247), comparing dasatinib 100 mg QD (n=259) with imatinib 400 mg QD (n=260) in newly diagnosed chronic phase CML (CML-CP), included a sizeable East Asian population (n=60: dasatinib; n=48: imatinib). In East Asian patients, dasatinib showed favorable 24-month rates of major molecular response (68% vs. 50% for imatinib) and complete cytogenetic response (92% vs. 88%), and more patients achieved BCR-ABL1 transcript levels ≤10% at 3 months with dasatinib (91% vs. 69%), similar to the overall population. Relative to non-East Asian patients, the incidence of rash, fluid-related events, and grade 3/4 neutropenia and thrombocytopenia appeared to be higher in East Asians, regardless of treatment. Pharmacokinetic analysis revealed statistically non-significant increased dasatinib exposure among East Asian patients. Results support the use of dasatinib 100 mg QD as first-line CML treatment in both East Asian and non-East Asian patients.

175
Stars
Star This?  Yes / No
 
1
Sign InSign In
inst val